On Aug. 20, 2021, Amyris announced promising in-vivo results in a study of its licensed RNA vaccine through intranasal delivery, developed in collaboration with the Infectious Disease Research Institute (IDRI).

In-vivo results indicated that, when delivered to the mucosal membranes via intranasal administration, the Amyris/IDRI RNA vaccine generated antibodies and provided upper respiratory protection for SARS-CoV-2 (COVID-19).